STING inhibitors in the form of competitive antagonists and covalent inhibitors have also been developed to treat autoinflammatory conditions such as Aicardi Goutières syndrome (AGS) and STING-associated vasculopathy with onset in infancy (SAVI) (Haag et al., 2018; Hansen et al., 2018). Here, STING1 is linked to STING-associated vasculopathy with onset in infancy.